195 related articles for article (PubMed ID: 26558443)
1. Impact of being overweight on factor VIII dosing in children with haemophilia A.
Henrard S; Hermans C
Haemophilia; 2016 May; 22(3):361-7. PubMed ID: 26558443
[TBL] [Abstract][Full Text] [Related]
2. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A.
Henrard S; Speybroeck N; Hermans C
J Thromb Haemost; 2011 Sep; 9(9):1784-90. PubMed ID: 21729239
[TBL] [Abstract][Full Text] [Related]
3. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
van Moort I; Preijers T; Hazendonk HCAM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Leebeek FWG; Meijer K; Mathôt RAA; Cnossen MH;
Br J Clin Pharmacol; 2021 Jun; 87(6):2602-2613. PubMed ID: 33232535
[TBL] [Abstract][Full Text] [Related]
4. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
5. Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A.
Tiede A; Cid AR; Goldmann G; Jiménez-Yuste V; Pluta M; Lissitchkov T; May M; Matytsina I; Miljic P; Pabinger I; Persson P
Thromb Haemost; 2020 Feb; 120(2):277-288. PubMed ID: 31887776
[TBL] [Abstract][Full Text] [Related]
6. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
8. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
[TBL] [Abstract][Full Text] [Related]
9. Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target.
Schütte LM; de Rooij N; Hazendonk HCAM; Mathôt RAA; van Hest RM; Leebeek FWG; Cnossen MH; Kruip MJHA
Haemophilia; 2019 Nov; 25(6):960-968. PubMed ID: 31487098
[TBL] [Abstract][Full Text] [Related]
10. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
[TBL] [Abstract][Full Text] [Related]
11. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
12. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
Björkman S; Folkesson A; Jönsson S
Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
[TBL] [Abstract][Full Text] [Related]
16. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
17. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
van Moort I; Preijers T; Bukkems LH; Hazendonk HCAM; van der Bom JG; Laros-van Gorkom BAP; Beckers EAM; Nieuwenhuizen L; van der Meer FJM; Ypma P; Coppens M; Fijnvandraat K; Schutgens REG; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH;
Lancet Haematol; 2021 Jul; 8(7):e492-e502. PubMed ID: 34171280
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery.
Preijers T; Laros-vanGorkom BA; Mathôt RA; Cnossen MH
BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30642854
[TBL] [Abstract][Full Text] [Related]
19. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
[TBL] [Abstract][Full Text] [Related]
20. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
